Background: Psoriasis is associated with risk of cardiovascular (CV) disease (CVD) and a major adverse CV event (MACE). Whether psoriasis duration affects risk of vascular inflammation and MACEs has not been well characterized.
Methods: First, patients with psoriasis (N = 190) underwent fludeoxyglucose F 18 positron emission tomography/computed tomography (duration effect reported as a b-coefficient). Second, MACE risk was examined by using nationwide registries (adjusted hazard ratios in patients with psoriasis (n = 87,161) versus the general population (n = 4,234,793).
Results: In the human imaging study, patients were young, of low CV risk by traditional risk scores, and had a high prevalence of cardiometabolic diseases. Vascular inflammation by fludeoxyglucose F 18 positron emission tomography/computed tomography was significantly associated with disease duration (b = 0.171, P = .002). In the population-based study, psoriasis duration had strong relationship with MACE risk (1.0% per additional year of psoriasis duration [hazard ratio, 1.010; 95% confidence interval, 1.007-
1.013]).
Limitations: These studies utilized observational data.
Conclusion:
We found detrimental effects of psoriasis duration on vascular inflammation and MACE, suggesting that cumulative duration of exposure to low-grade chronic inflammation may accelerate vascular disease development and MACEs. Providers should consider inquiring about duration of disease to counsel for heightened CVD risk in psoriasis. ( J Am Acad Dermatol 2017;77:650-6.)
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Patients with psoriasis have an increased incidence and prevalence of cardiovascular (CV) risk factors 1 and CV disease (CVD). [2] [3] [4] [5] Vascular inflammation by fludeoxyglucose F 18 positron emission tomography/computed tomography (18-FDG PET/CT), which is prognostic for future CV events, is increased in patients with psoriasis. [6] [7] [8] Cumulative exposure to inflammation is linked to increased atherosclerosis and CV events, suggesting that longer disease duration might increase the risk for CVD and CV events. Thus, disease duration may represent a potentially easily obtainable measure of risk for CVD in inflammatory-based diseases.
We investigated whether longer duration of psoriasis would increase vascular inflammation and a major adverse CV event (MACE) on account of the longer exposure to chronic, low-grade systemic inflammation observed in psoriasis.
MATERIALS AND METHODS
Detailed descriptions of study approvals, data sources, and methods are available online. 9 Study approval for the interventional cohort study was obtained from the National Heart, Lung, 
Data sources
Data for the cohort study at the National Heart, Lung, and Blood Institute were obtained under the protocol titled Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (NCT01778569). Complete and accurate data (including medical conditions, pharmacotherapy, treatment interventions and surgical procedures, income, and vital statistics) on the Danish population are available from nationwide registers, which can be linked at the individual level. patients with psoriasis who were recruited from January 2013 through June 2016. A dermatologist or a certified physician confirmed the onset and duration of psoriasis and assessed psoriasis severity using the Psoriasis Area Severity Index and body surface area scores. Clinical parameters, including blood pressure, height, weight, waist and hip circumferences, were measured. Laboratory parameters, including fasting blood glucose, fasting lipid panel, white blood count with differential, and systemic inflammatory markers (including highsensitivity C-reactive protein and erythrocyte sedimentation rate) were evaluated in a clinical laboratory. All patients underwent 18-FDG PET/CT scans for quantification of vascular inflammation. [6] [7] [8] Total Danish population cohort. The total Danish population cohort (henceforth population cohort) comprised all Danish citizens who were age 18 years or older, alive, and residing in Denmark on January 1, 2008 (the study start).
Outcomes
NIH cohort. The primary outcome in the NIH cohort was target-to-background ratio (TBR) assessed by 18-FDG PET/CT (Siemens Biograph mCT PET/CT 64-slice scanner, Siemens Healthcare, Malvern, PA). 18-FDG uptake within the aorta was measured by utilizing dedicated analysis software for PET/CT (Extended Brilliance Workspace [Phillips Healthcare, Andover, MA]). One value of TBR was used as the primary outcome for each patient. The association between vascular inflammation and MACEs was not examined. Detailed description of TBR calculation is provided in our previous work. 8 Population cohort. The primary outcome in the population cohort was the first occurrence of a MACE (ie, a composite of myocardial infarction
[MI], ischemic stroke, and CV death, respectively). Secondary outcomes included specific occurrences of MI, ischemic stroke, and death due to CV.
Covariates
NIH cohort. Baseline treatment for the NIH cohort was defined for any of the following therapies: systemic nonbiologic agents (henceforth systemic) or biologic therapy (systemic steroids, methotrexate, adalimumab, etanercept, and ustekinumab), statins, psoralen plus ultraviolet A (PUVA) or ultraviolet B (UVB), and topical treatments. Patients completed survey-based questionnaires regarding smoking, previous CVD, family history of CVD, and previous established diagnoses of hypertension and diabetes. Patient responses were then ascertained by interview with the physician. All parameters were assessed up to 12 months before study inclusion.
Population cohort. Baseline treatment up to 6 months before study inclusion was defined for the following therapies: biologics (adalimumab, efalizumab, etanercept, infliximab, and ustekinumab), cholesterol-lowering drugs, cyclosporine, methotrexate, PUVA/UVB, retinoids (acitretin/etretinate), and topical vitamin D analogues. Baseline comorbidity was assessed up to 5 years before study inclusion for the following conditions: alcohol abuse, smoking, CVD, diabetes, hypertension, and psoriatic arthritis. We calculated age-standardized socioeconomic status on the basis of average gross annual income during the 5-year period before study inclusion. 
Statistical analysis
Results were presented with 95% confidence intervals (CIs) where applicable, and P values less than 0.05 were considered statistically significant. Statistical analyses were performed with STATA software (versions 12.0 and 13.0, StataCorp, College Station, TX) and SAS software (version 9.4, SAS Institute, Inc, Cary, NC).
Summary statistics were presented as means with the standard deviation (SD) for normally distributed variables, medians, and interquartile range for nonnormally distributed continuous variables and frequencies for categorical variables. Normality was assessed by skewness and kurtosis. Parametric variables were compared between groups using the Student t test and the Mann-Whitney U test was performed for nonparametric variables. Dichotomous variable comparisons were done using Pearson's chi-square test.
NIH cohort. Unadjusted regression analyses were performed to evaluate for potential relationships between cardiometabolic variables and psoriasis duration. We conducted multivariable linear regression analyses to evaluate the associations of vascular inflammation (TBR) with psoriasis duration. These analyses were adjusted for age at onset of psoriasis, sex, and traditional CV risk assessed by Framingham risk score, history of CVD, diabetes, hypertension, treatment with statins, smoking, and alcohol abuse. We assessed the F statistics along with P values as well as the root mean squared error values to assess for the goodness of fit for every model.
Population cohort. Incidence rates were summarized per 1000 person-years, and Cox regression was performed to estimate hazard ratios (HRs). Multivariable models were adjusted for age, sex, socioeconomic status, previous CVD, smoking, alcohol abuse, diabetes, hypertension, and use of statins. We performed separate sensitivity analyses, from which patients with psoriatic arthritis and those with previous CVD, respectively, were excluded. We performed additional analyses in which psoriasis was defined by using only hospital diagnoses. Moreover, we did analyses in which the population cohort was divided into older (born before 1960) and younger (born in or after 1960) individuals, respectively. Lastly, we repeated our analyses with adjustment for age at onset of psoriasis. J AM ACAD DERMATOL VOLUME 77, NUMBER 4
RESULTS

NIH cohort
The NIH cohort comprised 190 patients with mildto-moderate psoriasis (Supplemental Table I ; available at http://www.jaad.org), who were primarily middle-aged men (57% men), overweight, with mild insulin resistance (median insulin resistance of 2.77), but at low CV risk by Framingham risk score. Vascular inflammation assessed by TBR (mean 6 SD = 1.70 6 0.26) demonstrated increased vascular inflammation. 10 Strong associations with vascular inflammation were seen for male sex, smoking, Framingham 10-year risk, and body mass index (BMI). The per-year incremental effect of psoriasis duration on vascular inflammation (assessed by TBR) showed that duration of psoriasis was associated with increased vascular inflammation (b = 0.086, P = .040), a relationship that persisted beyond adjustment for traditional CV risk factors (b = 0.171, P = .002) (Fig 1 and Supplemental Tables  II and III ; available at http://www.jaad.org).
Population cohort
The population cohort comprised 4,321,954 individuals, including 87,161 patients with psoriasis (maximum disease duration was 31.1 years) ( Table I) . During a mean (6SD) follow-up of 4.7 (0.9) years, MACEs were experienced by a total of 152,122 patients in the general population (incidence rate/1,000 person-years, 7.56 [95% CI, 7.52-7.60]) and 4472 patients with psoriasis (incidence rate/1,000 person-years, 10.94; [95% CI, 10.62-11.26]), respectively.
In unadjusted analyses, psoriasis was associated with 3.9% increased risk for MACEs per additional year of disease duration, and in multivariable analysis, the risk of MACEs increased by 1.0% per additional year of psoriasis duration (HR, 1.010; 95% CI, 1.007-1.013) (Table II and Fig 2) . For secondary end points, the multivariable HRs associated with duration of psoriasis were 1.006 (95% CI, 1.001-1.012) for MI, 1.011 (95% CI, 1.007-1.016) for ischemic stroke, and 1.011 (95% CI, 1.007-1.015) for CV death, respectively.
DISCUSSION
We utilized a human imaging study and a population-based study to investigate whether the duration of psoriasis increases the risk for CVD and MACEs, and we have presented novel and convincing evidence to suggest a detrimental effect of psoriasis duration on CVD beyond traditional CV risk factors, even in patients with low CV risk scores. Notably, every 1 SD increase in duration of psoriasis increases the TBR by 2.5%, which roughly translates into an absolute increase of 10% in future adverse events on the basis of a recent large population study.
11
As in the case of studies of rheumatoid arthritis, 12 most but not all studies have associated psoriasis with an increased risk for CVD, 2-5,13-15 yet data suggest that classic CV risk factors alone do not fully capture this heightened risk, and systemic inflammation has been put forward as a potential explanation for the link between psoriasis and CVD. Along this line, inflammation is associated with impaired insulin sensitivity, carotid intima-media thickening, endothelial dysfunction, aortic stiffness, vascular inflammation, and coronary plaque burden, with such CVD markers occurring more frequently in patients with psoriasis. [16] [17] [18] These insults could occur because of consistent vascular damage consequent to immune activation in those with longer duration of disease.
We opted for a translational epidemiologic approach, utilizing a human imaging study combined with observational registry data to emphasize the putative clinical relevance of increased vascular inflammation observed in our study. Specifically, we found a 1% increase in future CV event risk per additional year of disease duration, which is an effect size similar to that of smoking. Each of the components of the composite outcome of MACEs also increased with longer duration of disease, suggesting that duration of inflammation increases all vascular diseaseerelated events. Nevertheless, we emphasize that the independent association between psoriasis and CVD remains a topic of ongoing debate, 19 as does the effect of systemic therapy on the vascular inflammation and CV events. 20 A limitation in the population cohort was a lack of information for BMI and levels of physical exercise. However, such data were available in the NIH cohort, and adjustment for BMI did not significantly change the relationship between duration of disease and vascular inflammation. Furthermore, previous CVD and diabetes, which are two major predictors of MACEs in the population cohort, did not relate to vascular inflammation in the NIH cohort. This is likely due to the low number of patients with these characteristics in the NIH cohort. Important strengths include the sheer number of participants and the high accuracy of the nationwide registries, which minimized bias due to sex, age, concurrent medication, and socioeconomic status. Observational data alone from a single study are not sufficient to establish causality. However, comparable findings across different populations, which were obtained by using our approach of both observational and vascular imaging data, add strength and credibility to our findings, and the results are consistent with prior work demonstrating that duration of psoriasis is an independent risk factor for MI and coronary artery disease measured by angiography. 21, 22 In conclusion, we have provided strong novel evidence that duration of psoriasis increases vascular inflammation and the risk of MACEs. Providers should consider inquiring about duration of psoriasis when assessing CV risk stratification. 
Supplemental
